Nycomed US Inc. has appointed Brian Markison as president and chief executive officer of the newly created stand-alone company emerging from the acquisition of Nycomed A/S by Takeda Pharmaceuticals.


Nycomed US, Brian Markison, CEO, chief executive officer, president, Nycomed A/S, Takeda Pharmaceuticals, Jeff Bailey, COO, chief operating officer, John Golubieski, chief financial officer, Hakan Bjorklund, King Pharmaceuticals, Pfizer, pharmaceuticals








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Nycomed names Markison as CEO

August 1st, 2011

MELVILLE, N.Y. – Nycomed US Inc. has appointed Brian Markison as president and chief executive officer of the newly created stand-alone company emerging from the acquisition of Nycomed A/S by Takeda Pharmaceuticals.

Nycomed US said Monday that it also has named Jeff Bailey to the newly created position of chief operating officer and John Golubieski as chief financial officer.

"The board and I have full confidence that Brian's broad experience, stature in the industry and proven record of success make him the right person to lead Nycomed US as it becomes a stand-alone company and meets the challenges of the future," Hakan Bjorklund, CEO of Nycomed and chairman of Nycomed US, said in a statement. "We are further delighted that Brian already has attracted two industry veterans to add to the depth we have within Nycomed US."

Markison, who also will be a Nycomed US board member, formerly was chairman and CEO of King Pharmaceuticals, which he joined as COO before being promoted to president and CEO in 2004 and elected chairman in 2007. Prior to King, he held various senior leadership positions at Bristol-Myers Squibb.

"I am delighted, along with Jeff and John, to join the team at Nycomed US," Markison stated. "This is an exciting time for the company because we have the opportunity to grow aggressively and forge our future as an independent entity. Jeff and John are great additions to an already strong and focused management team, and I am confident we can leverage the company's financial strength and unique platform within the dermatology market to drive further growth in our business."

Bailey formerly served as the chief commercial officer of King-Pfizer Pharmaceuticals, while Golubieski spent the last six years as the senior vice president of financial planning and analysis at King-Pfizer Pharmaceuticals.

Nycomed US will continue to be owned by Nycomed's current private-equity owners. The company has its corporate offices in Melville, N.Y.; manufacturing facilities in Melville and Hicksville, N.Y.; a distribution center in Mechanicsburg, Pa.; and the Fougera and PharmaDerm marketing and sales divisions in Melville, N.Y., and Florham Park, N,J.

"Over the coming months, we anticipate updating the market with greater detail on developments from our strategic plan," Markison added. "We will look to aggressively expand our offerings by evaluating strategic acquisitions and partnerships to enhance our position as a leading dermatology player in the U.S. We also have the right board and shareholders in place to attract high-quality assets and professionals and to diversify our business and markets."

Advertisement